Lecture 3 - Autoimmune diseases Flashcards

1
Q

what are organs specific autoimmune diseases vs systemic autoimmune diseases ?

A

organic specific autoimmune diseases include type 1 diabetes mellitus, good pastures syndrome, multiple sclerosis, graves diseases, hashimotos etc

systemic autoimmune diseases include rheumatoid arthritis, scleroderma, sle, primary sjogrens syndrome, polymyositis etc

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

describe the type I classification of autoimmune diseases dependant on pathogenic mechanism

A

Type I: IgE mediated diseases. there is no direct evidence that IgE antibodies are involved in the pathogenesis of autoimmune diseases. however, IgE specific self antigens have been identified in autoimmune diseases of skin, thyroid, pancreas, eye, connective tissue and joints

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

describe Type II classification of autoimmune diseases based on pathogenic mechanism

A

type II autoimmune diseases are IgG or IgM mediated diseases.

types of type II mediated diseases include autoimmune haemolytic anaemia, autoimmune thrombocytopenia purpura, good pastures syndrome, pemphigus vulgarisms and acute rheumatic fever

ind myasthesisa gravis, Autoantibodies against the α subunit of the acetylcholine receptor, the binding leads to reduced numbers of receptor on the muscle

in good pastures disease, utoantibodies in Goodpasture’s disease cause local activation of cells that have Fc receptors,This binding leads to a series of immune responses, including complement activation, which is part of the immune system designed to destroy pathogens, and the influx of neutrophils

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Describe type III mediated autoimmune disease by the pathogenic mechanisms

A

type III autoimmune disease is mediated by immune complexes

mixed essential cryoglobulinemia, rheumatoid arthritis and sLE are types of type III mediated autoimmune disease

Immune complex deposition in tissues such as blood vessels, heart, joints, skin and kidneys, leading to activation of complement, stimulation of an inflammatory response, and recruitment and activation of neutrophils result in damage to tissues of these organs.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what are type IV mediated autoimmune diseases?

A

type IV mediated diseases include type 1 diabetes, rheumatoid arthritis and ,multiple sclerosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what is Polyautoimmunity and
multiple autoimmune syndrome (MAS)

A

About 25 percent of people with autoimmune diseases have atendency to develop additional autoimmune diseases

More than one diagnosed autoimmune disease, it’s called poly-autoimmunity. The combination of three or more diagnosed autoimmune disorders in one person is called MAS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what are some well described overlapping syndromes?

A

overlappign connective tissue disease features more than ien autoimmuen rheamtic disease

SLE, polymyositis, and scleroderma - mixed connective tissue disease (MCTD)

Limited cutaneous systemic sclerosis (CREST), primary biliary cirrhosis, Sjogren’s syndrome

Polymyositis and scleroderma

SLE and rheumatoid arthritis

SLE and scleroderma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what is the treatment for autoimmune diseases?

A

Reduce inflammation and pain – anti-inflammatory drugs

Reduce inflammation – Corticosteroids

Manage pain – e.g. paracetamol and codeine

Immunosuppressant drugs – to inhibit the active immune response and reduce inflammation

Treatment for deficiency – e.g. insulin for T1D

Surgery - treat bowel blockage in Crohn’s disease

Physical therapy – to encourage mobility

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

describe the basic of rheamotid arthritis.

A

An inflammatory joint disorder primarily characterised by symmetrical polyarticular synovitis. affects females 2-3 times more than males, more common 25 to 50 years of age, reduced life expectancy and increased disability ,

A systemic disease – but, in the early stages it is only an articular disease (early morning stiffness, fatigue, joint swelling and pain), the systemic extra-articular manifestations (lung, kidney, blood vessels, muscles or neurological system) developing at the late stage of the disease.

in osteoarthritis bone ends rub together and there is thinned cartilage. in rhematoid arthritis there is bone erosion and swollen inflammed synovial membrane

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what is the ethology of rheumatoid arthritis?

A

generally unknown, genetic predisposition is HLA-DR4 antigen increases risk by 5 times. Environmental, infection (suspected infectious organisms triggering RA include mycoplasma, rebella, parvovirus or EBV), diet, trauma or psychological factors may play a role in initiating immune response.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what are clinical features of rheumatoid arthritis?

A

the onset insidious in 70%. often begins with ache and morning stiffness lasting >30 minutes and gets better with motion. most common presentation of polyarticular
and symmetric especially of small joint of feet and hands.

forefoot symptoms may appear in up to 20% of patients initially and may be more common than reported but tolerated by patients until other symptoms develop eg fingers develop

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what are systemic autoimmune disease with extra-articular manifestations (symptoms outside joints)

A

weightless, skin, eye, respiratory, cardiac, renal, haematological, gastrointestinal, Hand deformities, cervical spine involvement

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what do lab results show in rheumatoid arthritis?

A

Blood – increased ESR in 90%;

rheumatoid factor - if you have RA and you have rheumatoid factor or other certain auto-antibodies in your blood, it could mean that your RA is more serious and may affect more than just your joints.

synovial fluid and increased white blood cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what changes does an x-ray show in synovial joints in someone with rheumatoid arthritis?

A
  1. initially soft tissue swelling, widening of joint space with some osteoporosis.
  2. Later: periarticular osteoporosis and uniform narrowing of joint space. marginal cortical bone erosions, subchondral bone erosions and cysts form, subluxations. In end stages may get bony ankylosis.
  3. Evidence of erosive damage to bone is seen in 45% patients on MRI within 4 months of symptom onset and 75% with 2 years
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what s the rheumatoid arthritis criteria for diagnosis?

A

Four of the following criteria are required to diagnosis:
morning stiffness (> 1 hr for more than 6 weeks)

arthritis of three or more joints for greater than 6 weeks

arthritis of hand joints for more than 6 weeks

symmetrical arthritis for more than 6 weeks

rheumatoid nodules

serum rheumatoid factor

radiographic changes (including erosions or bony decalcification)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what is the pathogenesis of rheumatoid arthritis?

A

inciting agent activates the immune system causing immunological reactions, immune complexes in synovial fluid activate complement and there is an inflammatory resposne leading to joint destruction.

17
Q

what are methods of rheumatoid arthritis management ?

A

patient education and motivation, physiotherapy, occupational therapy, good nutrition, exercise, complementary/ alternative therapies, surgical treatment

18
Q

what is the treatment for rheumatoid arthritis?

A

There is no cure for RA, the goal of pharmacological management is to relieve symptoms, prevent joint damage and put the disease into remission.

NSAID’s are commonly used early, but disease-modifying agents are now being used earlier.

Biological agents, disease-modifying anti-rheumatic drugs (DMARDs).

More aggressive approaches – combination of drugs is common approach now as many of them are not as effective if used as monotherapy.

Delay of treatment often leads to poorer outcome

19
Q

what is multiple sclerosis?

A

chronic inflammatory demyelination disease that affects the cns. most common neurological condition among young adults but MS is a diseases of all ages. higher in females than males

20
Q

what is the ethology of multiple sclerosis?

A

MS is not a hereditary disease, genetic variation can increase the risk of developing MS. people who live further from equator more likely to have MS. ms is also more likely to strike those with Scottish genes

21
Q

what are signs and symptoms of multiple sclerosis?

A

chances in sensation: muscle weakness and muscle spasm, or moving difficulty in moving,
coordination and balance; problems in speech, fatigue, acute or
chronic pain; bladder and bowel difficulties and cognitive impairment.

22
Q

what are multiple sclerosis clinical subtypes ?

A

Progressive relapsing MS
–Steady decline since onset

Secondary progressive MS
–initial RRMS that suddenly begins to have decline without period of remission

Primary progressive MS
–steady increase in disability without attacks

Relapsing and remitting MS
–unpredictable attacks followed by periods of remission

23
Q

describe the pathogenesis of multiple sclerosis

A
  1. Something initiates inflammation in the brain, making the blood-brain barrier permeable to lymphocytes and proteins.
  2. T cells that are specific to CNS antigens get activated in the periphery, then recognize and bind to these antigens presented by brain immune cells (microglia or dendritic cells).
  3. Inflammatory Reaction: The immune response escalates, with more immune cells activated, release of antibodies, and inflammatory molecules called cytokines.
  4. This demyelination impairs nerve signal transmission, causing the symptoms of MS
24
Q

describe the role of T cells in autoimmune Encephalomyelitis.

A

EAE can be induced in mice by injecting them with myelin basic protein along with complete Freund’s adjuvant and causes mice to become paralysed

Th1 cells mediate the disease. These Th1 cells are specific for myelin basic protein and upon activation, they release pro-inflammatory cytokines, which contribute to the inflammatory response in the CNS and the subsequent damage to the myelin sheath.

EAE can be transmitted from one mouse to another through the transfer of T cells so they can induce the disease in another host, demonstrating the centrality of T cells in the pathogenesis of EAE

25
Q

what is the treatment fro multiple sclerosis?

A

receive the pain and discomfort and prevent sight loss due to the disease or its complications. important to treat the cause of the disease where possible

Disease mdofyign treatments such as interferon beta1a, 1b, glatiramer acetate, mitoxantrone and natalizumab can be used

26
Q

descried glatiramer acetate as a treatment drug for MS

A

Glatiramer acetate(GA, a synthetic amino acid copolymer, brand name is Copaxone) is an immunomodulatormedication used to treatMultiple sclerosis. GA is approved to treat Relapse remitting multiple sclerosis and clinically isolated syndrome (CIS), it reduce the frequency of relapses, but not for reducing the progression of disability.

It is a mixture of random-sized peptides that are composed of the four amino acids found inmyelin basic protein: glutamic acid, lysine, alanine and tyrosine.

27
Q

describe the drug ocrelizumab

A

Ocrelizumab is used to treat ‘active’ relapsing MS. Its licence allows it to be used for early primary progressive MS too. It’s now recommended to be used on the NHS across the UK to treat both these types of MS.

It is ahumanizedanti-CD20monoclonal antibody.It targets CD20 marker onB lymphocytesand hence is animmunosuppressive drug. Ocrelizumab binds to anepitopethat overlaps with the epitope to whichrituximabbinds.

28
Q

describe fingolimod as a treatment drug for Multiple sclerosis

A

Fingolimod is asphingosine-1-phosphate receptor modulator, which sequesters lymphocytes in lymph nodes, preventing them from contributing to an autoimmune reaction (stops immune cells leaving lymph nodes and getting into CNS).

Fingolimod is more effective and less side effects than GA but less potent than alemtizuman and natalizumba which have more serious side effects